Compare ESI & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESI | BLCO |
|---|---|---|
| Founded | 1922 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Ophthalmic Goods |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 6.0B |
| IPO Year | 2014 | 2022 |
| Metric | ESI | BLCO |
|---|---|---|
| Price | $37.57 | $16.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $34.36 | $18.45 |
| AVG Volume (30 Days) | ★ 2.7M | 417.4K |
| Earning Date | 04-24-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | $2,551,200,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $21.08 | $8.63 |
| Revenue Next Year | $7.28 | $5.58 |
| P/E Ratio | $47.11 | ★ N/A |
| Revenue Growth | 3.84 | ★ 6.47 |
| 52 Week Low | $17.77 | $10.45 |
| 52 Week High | $37.75 | $18.92 |
| Indicator | ESI | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 66.10 | 49.85 |
| Support Level | $24.31 | $16.35 |
| Resistance Level | N/A | $16.81 |
| Average True Range (ATR) | 1.35 | 0.47 |
| MACD | 0.42 | 0.11 |
| Stochastic Oscillator | 92.36 | 72.63 |
Element Solutions Inc is a specialty chemicals company whose businesses supply a broad range of solutions that enhance the performance of products people use every day. The company's reportable segments are Electronics and Industrial & Specialty. The Electronics segment, which generates maximum revenue, researches, formulates, and sells specialty chemicals and process technologies for all types of electronics hardware, from complex printed circuit board designs to semiconductor packaging. This segment's wet chemicals for metallization, surface treatments, and solderable finishes form the physical circuitry pathways, and its assembly materials, such as solder, pastes, fluxes, and adhesives, join those pathways together.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.